We see a similar magnitude in Aβ peptide reduction from both the control and the APPDp cell lines, suggesting that HDAC2 does not impact this pathway differently based on the presence or absence of a familial AD mutation and thus may be beneficial in several treatment scenarios. The gene discussed is HDAC2; the disease is Alzheimer disease.